Oppenheimer & Co. Inc. Takes $625,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Oppenheimer & Co. Inc. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 9,802 shares of the biopharmaceutical company's stock, valued at approximately $625,000.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after buying an additional 386,618 shares during the period. Snyder Capital Management L P boosted its position in Halozyme Therapeutics by 2.6% in the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock valued at $199,294,000 after buying an additional 105,086 shares during the period. Congress Asset Management Co. boosted its position in Halozyme Therapeutics by 8.8% in the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock valued at $136,088,000 after buying an additional 172,971 shares during the period. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock valued at $92,446,000 after buying an additional 47,795 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after purchasing an additional 145,617 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on HALO shares. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Finally, Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Stock Up 0.4%

Shares of NASDAQ HALO traded up $0.21 during trading hours on Friday, hitting $54.05. 868,065 shares of the stock were exchanged, compared to its average volume of 1,752,173. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13. The company has a market cap of $6.66 billion, a PE ratio of 14.38, a PEG ratio of 0.36 and a beta of 1.15. The firm has a fifty day moving average price of $55.49 and a 200-day moving average price of $56.57. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics's revenue was up 35.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.79 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total transaction of $1,074,600.00. Following the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $39,422,721.87. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the sale, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,497 shares of company stock worth $2,405,284. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.